Jade Biosciences (JBIO) Free Cash Flow (2020 - 2026)

Jade Biosciences has reported Free Cash Flow for 7 years, with the latest figure at -$24.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 28.45% year-over-year to -$24.1 million; the trailing twelve-month figure through Mar 2026 stood at -$100.2 million (down 108.03% YoY), and the FY2025 full-year result was -$94.9 million, down 33.27% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$24.1 million, up from -$33.7 million in the prior quarter.
• The five-year high for Free Cash Flow was -$5.7 million in Q1 2022, with the low at -$33.7 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$16.8 million across 5 years, with a median of -$15.3 million in 2022.
• Annual changes were most pronounced in 2024 — Free Cash Flow surged 56.48% — and 2025, when it tumbled 227.51%.
• Jade Biosciences' Free Cash Flow stood at -$15.0 million in 2022, then increased by 0.98% to -$14.9 million in 2023, then tumbled by 52.0% to -$22.6 million in 2024, then tumbled by 48.99% to -$33.7 million in 2025, then gained by 28.47% to -$24.1 million in 2026.
• The last three Free Cash Flow figures came in at -$24.1 million (Q1 2026), -$33.7 million (Q4 2025), and -$22.3 million (Q3 2025), per Business Quant data.